Rigel Readies Tavalisse For Late-May Launch After FDA Approval
Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.
You may also be interested in...
The cancer drug developer led by former Gilead R&D head Norbert Bischofberger will start a registrational trial for its recently acquired SYK inhibitor and the first trial for its CDK9 inhibitor.
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.